Profund Advisors LLC Has $1.26 Million Position in Syndax Pharmaceuticals, Inc. $SNDX

Profund Advisors LLC lifted its holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 94.8% in the 4th quarter, Holdings Channel.com reports. The firm owned 60,038 shares of the company’s stock after buying an additional 29,221 shares during the quarter. Profund Advisors LLC’s holdings in Syndax Pharmaceuticals were worth $1,261,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of the business. Larson Financial Group LLC raised its holdings in Syndax Pharmaceuticals by 192.2% during the 3rd quarter. Larson Financial Group LLC now owns 2,922 shares of the company’s stock worth $45,000 after buying an additional 1,922 shares during the period. Quantbot Technologies LP acquired a new position in shares of Syndax Pharmaceuticals in the third quarter valued at approximately $53,000. Lazard Asset Management LLC bought a new stake in shares of Syndax Pharmaceuticals during the second quarter worth $66,000. Tower Research Capital LLC TRC increased its position in shares of Syndax Pharmaceuticals by 103.3% during the second quarter. Tower Research Capital LLC TRC now owns 8,480 shares of the company’s stock worth $79,000 after acquiring an additional 4,308 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Syndax Pharmaceuticals by 26.8% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,223 shares of the company’s stock worth $89,000 after acquiring an additional 893 shares during the period.

Syndax Pharmaceuticals Stock Performance

Shares of SNDX opened at $20.13 on Thursday. The stock has a market capitalization of $1.78 billion, a price-to-earnings ratio of -7.22 and a beta of 0.41. Syndax Pharmaceuticals, Inc. has a 12 month low of $8.59 and a 12 month high of $25.59. The firm has a fifty day simple moving average of $22.82 and a 200 day simple moving average of $20.94. The company has a current ratio of 5.47, a quick ratio of 5.06 and a debt-to-equity ratio of 8.26.

Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its quarterly earnings results on Thursday, April 30th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.59) by $0.11. Syndax Pharmaceuticals had a negative net margin of 111.88% and a negative return on equity of 256.65%. The firm had revenue of $64.86 million for the quarter, compared to analyst estimates of $69.76 million. During the same period in the previous year, the business earned ($0.98) EPS. The company’s revenue was up 224.3% compared to the same quarter last year. Research analysts forecast that Syndax Pharmaceuticals, Inc. will post -1.66 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on SNDX shares. Mizuho cut their price objective on shares of Syndax Pharmaceuticals from $45.00 to $43.00 and set an “outperform” rating on the stock in a research report on Tuesday, March 31st. JPMorgan Chase & Co. lifted their price target on Syndax Pharmaceuticals from $33.00 to $45.00 and gave the company an “overweight” rating in a research note on Monday, March 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Syndax Pharmaceuticals in a report on Friday, March 27th. Stifel Nicolaus set a $45.00 price objective on Syndax Pharmaceuticals in a research report on Friday, February 27th. Finally, The Goldman Sachs Group increased their price objective on Syndax Pharmaceuticals from $28.00 to $34.00 and gave the stock a “buy” rating in a report on Wednesday, April 1st. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Syndax Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $42.55.

Syndax Pharmaceuticals Profile

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of cancer. Headquartered in Waltham, Massachusetts, the company focuses on small-molecule inhibitors that target key epigenetic and protein interaction pathways. Syndax’s research platform aims to enhance the effectiveness of existing therapies and address high unmet medical needs in oncology.

The company’s lead investigational candidate, entinostat, is a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications.